Mouse Anti-ESR1 Recombinant Antibody (503) (CBMAB-1209-YC)

Basic Information
Application | Note |
WB | 1:100-1:1,000 |
IP | 1-2 µg per 100-500 µg of total protein (1 ml of cell lysate) |
Formulations & Storage [For reference only, actual COA shall prevail!]
Target
Isoform 3:
Involved in activation of NOS3 and endothelial nitric oxide production (PubMed:21937726).
Isoforms lacking one or several functional domains are thought to modulate transcriptional activity by competitive ligand or DNA binding and/or heterodimerization with the full-length receptor (PubMed:10970861).
Binds to ERE and inhibits isoform 1 (PubMed:10970861).
Antral ovarian follicle growth Source: Ensembl
Cellular response to estradiol stimulus Source: ARUK-UCL
Cellular response to estrogen stimulus Source: Ensembl
Chromatin remodeling Source: UniProtKB
Epithelial cell development Source: Ensembl
Epithelial cell proliferation involved in mammary gland duct elongation Source: Ensembl
Intracellular estrogen receptor signaling pathway Source: CAFA
Intracellular steroid hormone receptor signaling pathway Source: UniProtKB
Male gonad development Source: Ensembl
Mammary gland alveolus development Source: Ensembl
Mammary gland branching involved in pregnancy Source: Ensembl
Negative regulation of DNA-binding transcription factor activity Source: UniProtKB
Negative regulation of gene expression Source: UniProtKB
Negative regulation of I-kappaB kinase/NF-kappaB signaling Source: UniProtKB
Negative regulation of production of miRNAs involved in gene silencing by miRNA Source: BHF-UCL
Negative regulation of transcription by RNA polymerase II Source: BHF-UCL
Phospholipase C-activating G protein-coupled receptor signaling pathway Source: UniProtKB
Positive regulation of cytosolic calcium ion concentration Source: UniProtKB
Positive regulation of DNA-binding transcription factor activity Source: UniProtKB
Positive regulation of fibroblast proliferation Source: Ensembl
Positive regulation of nitric oxide biosynthetic process Source: UniProtKB
Positive regulation of nitric-oxide synthase activity Source: UniProtKB
Positive regulation of phospholipase C activity Source: UniProtKB
Positive regulation of RNA polymerase II transcription preinitiation complex assembly Source: CAFA
Positive regulation of transcription, DNA-templated Source: UniProtKB
Positive regulation of transcription by RNA polymerase II Source: UniProtKB
Prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis Source: Ensembl
Prostate epithelial cord elongation Source: Ensembl
Protein localization to chromatin Source: BHF-UCL
Regulation of apoptotic process Source: Ensembl
Regulation of branching involved in prostate gland morphogenesis Source: Ensembl
Regulation of inflammatory response Source: Ensembl
Regulation of toll-like receptor signaling pathway Source: Ensembl
Regulation of transcription, DNA-templated Source: UniProtKB
Regulation of transcription by RNA polymerase II Source: GO_Central
Response to estradiol Source: BHF-UCL
Response to estrogen Source: UniProtKB
Signal transduction Source: ProtInc
Stem cell differentiation Source: Ensembl
Uterus development Source: Ensembl
Vagina development Source: Ensembl
Isoform 3: Cell membrane; Nucleus; Cytoplasm. Associated with the inner membrane via palmitoylation (Probable). At least a subset exists as a transmembrane protein with a N-terminal extracellular domain.
Cell membrane; Golgi apparatus; Nucleus. Colocalizes with ZDHHC7 and ZDHHC21 in the Golgi apparatus where most probably palmitoylation occurs. Associated with the plasma membrane when palmitoylated.
A disorder characterized by partial or complete resistance to estrogens, in the presence of elevated estrogen serum levels. Clinical features include absence of the pubertal growth spurt, delayed bone maturation, unfused epiphyses, reduced bone mineral density, osteoporosis, continued growth into adulthood and very tall adult stature. Glucose intolerance, hyperinsulinemia and lipid abnormalities may also be present.
Glycosylated; contains N-acetylglucosamine, probably O-linked.
Ubiquitinated; regulated by LATS1 via DCAF1 it leads to ESR1 proteasomal degradation (PubMed:21602804, PubMed:28068668). Deubiquitinated by OTUB1 (PubMed:19383985).
Dimethylated by PRMT1 at Arg-260. The methylation may favor cytoplasmic localization (PubMed:18657504, PubMed:24498420). Demethylated by JMJD6 at Arg-260 (PubMed:24498420).
Palmitoylated (isoform 3). Not biotinylated (isoform 3).
Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation is required for plasma membrane targeting and for rapid intracellular signaling via ERK and AKT kinases and cAMP generation, but not for signaling mediated by the nuclear hormone receptor.
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.
Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols
Related Products
Mouse Anti-ESR1 Recombinant Antibody (CBT4339) (CAT#: V2LY-0625-LY650)
Mouse Anti-ESR1 Recombinant Antibody (C9) (CAT#: CBMAB-E1870-FY)
Mouse Anti-ESR1 Recombinant Antibody (G6) (CAT#: CBMAB-E1865-FY)
Mouse Anti-ESR1 Recombinant Antibody (CBT516) (CAT#: V2LY-0625-LY3456)
Mouse Anti-ESR1 Recombinant Antibody (23) (CAT#: CBMAB-1204-YC)
Mouse Anti-ESR1 Recombinant Antibody (27) (CAT#: CBMAB-1186-YC)
Mouse Anti-ESR1 Recombinant Antibody (CBT2465) (CAT#: V2LY-0625-LY2287)
Mouse Anti-ESR1 Recombinant Antibody (CBT4734) (CAT#: V2LY-0625-LY2277)
Mouse Anti-ESR1 Recombinant Antibody (CBT3942) (CAT#: V2LY-0625-LY2533)
Custom Antibody Labeling
We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).
Online InquiryContact us
